Allogenica selected for the Women TechEU program
- Voisin Céline
- Jul 3
- 1 min read
We’re proud to share exciting news: Inna Menkova, CEO of Allogenica, has been selected as a winner of the prestigious Women TechEU program, launched by the European Commission.
Women TechEU is a two-year EU-funded initiative launched in 2024 to support women leading deep tech startups across Europe and Associated Countries. Its mission is to foster a more gender-balanced entrepreneurship ecosystem — because diversity drives innovation. A total of 160 beneficiaries were selected through a highly competitive evaluation process.
Being chosen as a Women TechEU winner is a strong mark of excellence and recognition of Allogenica’s mission to transform cancer treatment. This support connects our company to a vibrant European network of investors, experts, and decision-makers.
Our approach to next-generation T cell therapy
T cell therapies are transforming cancer care, yet current autologous approaches remain slow, expensive, and patient-specific.
At Allogenica, we are developing universal, off-the-shelf T cell therapies that are accessible, scalable, and fast. Our patented platform uses immature T cells from healthy donors, genetically edited with non-viral, precise tools to:
Avoid immune rejection
Be educated as part of the patient’s immune system
Significantly reduce production time and cost
Our goal: bring powerful immunotherapies to more patients, faster and at lower cost — especially those facing hard-to-treat cancers and limited therapeutic options.
🎥 Discover our vision in the Women TechEU application video: Watch the video
Congratulations again to Inna Menkova for this well-deserved recognition of her vision, leadership, and commitment to driving innovation in immunotherapy.
